Calcium balance and regulation in schizophrenic patients treated with second generation antipsychotics;Zaburzenia gospodarki wapniowo-fosforanowej u chorych na schizofreniȩ leczonych lekami przeciwpsychotycznymi II generacji

Psychiatria Polska

Volumn 39, Issue 6, 2005, Pages 1157-1171

  Wyszogrodzka Kucharska, Anna ^a,b   Rabe Jabłońska, Jolanta ^b  

^a Centralny Szpital Kliniczny   (Poland)

^b UM   (Poland)

Author keywords

Calcium balance and regulation; Schizophrenia; Second generation antipsychotics

Indexed keywords

CALCIFEDIOL; CALCIUM; OLANZAPINE; PARATHYROID HORMONE; PHOSPHATE; RISPERIDONE;

ADULT; ARTICLE; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; SCHIZOPHRENIA;

EID: 31044454117     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Baastrup PC, Christiansen C, Transbil I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiol. 1980; 6: 56-59.
2. Arden NK, Spector TD, red. Osteoporoza, aktualny stan wiedzy. Warszawa: Wydawnictwo Medyczne Borgis; 2000.
3. Lewinski A. Gospodarka wapniowo-fosforanowa, diagnostykajej zaburzeń. W: Traczyk WZ, red. Diagnostyka czynnościowa człowieka. Fizjologia stosowana. Warszawa: PZWL, 1999.
4. Komoda T, Ikeda E, Nakatani Y, Sakagishi Y. Inhibitory effect of phenotiazine derivates on bone in vivo and osteoblastic cells in vitro. Biochem. Pharmacol. 1985; 34: 3885-3889.
5. Komoda T, Nagata A, Kiyoki M, Miura M, Koyama I, Sakagishi Y, Kumegawa M. Chlorpromazine alters bone metabolism of rats in vivo. Calcif. Tissue Int. 1988; 42(1): 58-62.
6. Higuchi T, Komoda T, Sugishita M, Yamazaki J, Miura M, Sakagishi Y, Yamauchi T. Certain neuroleptics reduce bone mineralization in schizophrenic patients. Neuropsychobiol. 1987; 18: 185-188.
7. Climent-Lacroix P, Ormady C, Lepescheux L. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinol. 1999; 140: 96-105.
8. Coss D, Yang L, Kuo CB, Xu X, Luben RA, Walker AM. Effects of prolactin on osteoblast alkaline phosphatase on bone formation in the developing rat. Am. J. Physiol. Endocrinol. Metab. 2000; 279(6): 1216-1225.
9. Bouillon R, Reynaert J, Claes JH, Lissens W, De Moor P. The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D, calcium, parathyroid hormone. J. Clin. Endocrinol. Metab. 1975; 41: 1130-1135.
10. De Leon J, Verghese C, Tracy J, Josiassen RC, Simpson GM. Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. Biol. Psychiatry 1994; 35: 408-419.
11. Delva NJ, Crammer JL, Janyło SV, Lawson JS, Owen JA, Sribney M, Weir BJ, Yendt ER. Osteopenia, pathological fractures and increased calcium excretion in schizophrenic patients with polydipsia. Biol. Psychiatry 1989; 26: 781-793.
12. Wyszogrodzka-Kucharska A, Rabe-Jabłońska J. Czynniki ryzyka rozwoju osteoporozy u pacjentów ze schizofrenia̧ - wskazania do profilaktyki i leczenia osteoporozy. Post. Psychiatr. Neurol. 2002; 11: 37-41.
13. Adler RA, Farrell ME, Dess WP, Krieg RJ, MacLeod RM. Hypercalcuria in a new rat model of hyperprolactinemia. Metabol. 1991; 40(3): 292-296.
14. Abraham EJ, Villalobos C, Frawley SL. Effects of cellular interactions on calcium dynamics on prolactin-secreting cells. Endocrinol. 1997; 139(6): 2988-2993.
15. Hahn TJ. Bone complications of anticonvulsants. Drugs 1976; 12: 201-211.
16. Hoikka V, Alhava EM, Karjalainen P. Carbamazepine and bone mineral metabolism. Acta Neurol. Scand. 1984; 69: 77-80.
17. Abraham G, Friedman RH, Verghese C, de Leon J. Osteoporosis and schizophrenia: can we limit known risk factors? Soc. Biol. Psychiatry 1995; 38: 1171-1172.